Abatacept is a synthetic fusion protein that blocks T cell activation. Hypersensitivity reactions (HSRs) are rare with Abatacept.
Early HSR developed at the first dose of abatacept in a 42-year-old patient diagnosed with rheumatoid arthritis (RA). Desensitization was planned with this drug as the treatment will be continued with abatacept. Since desensitization with Abatacept is not in the literature, a protocol was created for this drug. With this protocol, a weekly dose of 125 mg / ml was given in 4 hours. An allergic reaction did not develop after desensitization. The drug was tolerated with the rapid desensitization protocol.